Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro
M. Jang, Y.-I. Park, R. Park, Y.-E. Cha, S. Namkoong, J. I. Lee, J. Park
Abstract
COVID-19 has caused over 900,000 deaths worldwide as of September 2020, and effective medicines are urgently needed. Lopinavir was identified as an inhibitor of the HIV protease, and a lopinavir-ritonavir combination therapy was reported to be beneficial for the treatment of SARS and MERS. However, recent clinical tests could not prove that lopinavir-ritonavir therapy was an effective treatment for COVID-19. In this report, we examined the effect of lopinavir and ritonavir to the activity of the purified main protease (Mpro) protein of SARS- CoV-2, the causative virus of COVID-19. Unexpectedly, lopinavir and ritonavir did not inhibit Mpro activity. These results will aid the drug candidate selection for ongoing and future COVID-19 clinical trials.
02 /Specification & Classification
Click any tag to browse matching papers- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
N. Fintelman-Rodrigues, C. Q. Sacramento, … T. M. L. Souza·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 21, 2020
- Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
M. M. Ghahremanpour, J. Tirado-Rives, … W. L. Jorgensen·bioRxiv·Aug 28, 2020
- Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.
N. Yamamoto, S. Matsuyama, … N. Yamamoto·bioRxiv·Apr 6, 2020
- A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.
J. D. Baker, R. L. Uhrich, … B. C. Kraemer·PLOS ONEPeer-reviewed·Feb 1, 2021
- Novel inhibitors against COVID-19 main protease suppressed viral infection
V. Ramachandran, Y. Liu, … R. Chang·bioRxiv·Nov 5, 2022
- Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-MPro inhibitors with potent in vivo efficacy
Tyler C. Detomasi, Gilles Degotte, … Charles S. Craik·Science AdvancesPeer-reviewed·Apr 23, 2025